PEG-Fentanyl Conjugates Reduce CNS Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Opioid agonists used for pain management are associated with potential abuse and significant first-pass metabolism, leading to CNS-mediated effects such as slowed breathing, which can be fatal, and lack specificity for opioid receptors, necessitating a reduction in these characteristics for enhanced therapeutic desirability.
Innovation Solution
Development of chemically modified opioid agonists by covalently attaching a water-soluble, non-peptidic oligomer to opioid agonists, specifically mu opioid agonists, to reduce metabolism and CNS penetration, thereby enhancing specificity and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid agonists are administered for pain management, then analgesic efficacy is achieved, but first-pass metabolism and CNS penetration cause harmful effects such as slowed breathing and potential death
Solution Approach 1:
A water-soluble oligomer is introduced as an intermediary component that is covalently attached to the opioid agonist. This oligomer acts as a mediator that reduces CNS penetration and first-pass metabolism while preserving analgesic efficacy at peripheral pain sites, thereby eliminating the harmful breathing effects associated with direct CNS opioid action
Solution Approach 2:
The invention creates a composite molecular structure by covalently linking the opioid agonist to a water-soluble oligomer. This composite conjugate combines the analgesic properties of the opioid with the beneficial pharmacokinetic properties of the oligomer, including reduced metabolism and restricted CNS access, achieving both pain relief and safety
2Ease of operation
If opioid agonists are administered orally, then convenience of administration is improved, but significant first-pass metabolism reduces drug availability and increases toxicity risk
Solution Approach 1:
The water-soluble oligomer serves as a protective intermediary that shields the opioid agonist from metabolic degradation during first-pass metabolism. This intermediary structure reduces the extent of hepatic metabolism, allowing more of the administered drug to reach systemic circulation in active form, thereby improving oral bioavailability while maintaining administration convenience
3Reliability
If opioid agonists are designed for high potency, then analgesic efficacy is improved, but selectivity for mu receptors decreases leading to abuse potential and off-target effects
Solution Approach 1:
The oligomer-conjugated opioid agonist exhibits local quality differentiation in its pharmacological action: the opioid portion maintains high affinity and selectivity for mu receptors at the target site to provide effective analgesia, while the oligomer portion provides localized protective effects by preventing metabolism and restricting CNS penetration, creating a spatially differentiated therapeutic profile that enhances both efficacy and safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugation of opioid agonists with water-soluble oligomers results in reduced metabolism and CNS penetration, enhancing specificity for mu opioid receptors and minimizing adverse effects like slowed breathing, while maintaining analgesic efficacy.
Implementation Method 1
covalently attached via a stable linkage to a water-soluble, non-peptidic oligomer
Data Source
Figure 1
Figure 2a~2b
Figure 3
AI summary
This invention provides conjugates wherein the opioid agonist fentanyl is covalently attached to poly(ethylene glycol) oligomers. A conjugate of the invention when administered by any of a number of administration routes, exhibits characteristics that are different from those of the opioid agonist not attached to the PEG oligomers.